Vitamin B5, Coenzyme A, and Energy Metabolism

Pantothenic acid (vitamin B5) as the precursor to coenzyme A — essential for fatty acid metabolism, energy production, and acyl carrier protein function, with emerging clinical evidence in acne and inherited neurodegeneration

Pantothenic acid is vitamin B5 — its name comes from the Greek "pantothen," meaning "from everywhere," because it shows up in nearly every food you eat [3]. Your body uses it to build coenzyme A (CoA), the molecule that carries fragments of fats, sugars, and proteins through hundreds of metabolic reactions every second [2]. Frank deficiency is exceedingly rare in people eating ordinary diets, but B5 has earned attention for one stubborn issue: a randomized trial found a pantothenic acid blend significantly reduced facial acne blemishes versus placebo [1].

What Pantothenic Acid Actually Does

Vitamin B5's main job is being the backbone of coenzyme A (CoA) — arguably the busiest cofactor in human biochemistry. CoA carries acetyl groups and other acyl groups into and out of the reactions that make energy, build cell membranes, and synthesize cholesterol, steroid hormones, neurotransmitters, and hemoglobin [2][3]. Roughly 4% of all enzymes in mammalian cells use CoA or one of its acyl derivatives as a substrate [3].

CoA is also the structural core of acyl carrier protein (ACP), the long arm that shuttles growing fatty acid chains during fat synthesis. Without B5, you can't build CoA; without CoA, you can't run the citric acid cycle, the fatty acid pathway, or hundreds of other reactions that depend on activated acyl groups [2].

Food Sources and Daily Intake

The U.S. Adequate Intake (AI) for adults is 5 mg/day; pregnancy raises it to 6 mg and lactation to 7 mg [2][4]. Because pantothenic acid is so widely distributed in food, average intake in industrialized countries comfortably meets the AI without supplementation [3][6]. Particularly rich sources include:

Organ meats — beef liver delivers about 8 mg per 3-oz serving (more than a full daily AI) [2]
Mushrooms — shiitake mushrooms are unusually high (about 5 mg per cup cooked) [2]
Sunflower seeds — about 2 mg per ounce
Avocado — roughly 2 mg in a whole fruit
Eggs, salmon, chicken, dairy, broccoli, sweet potato, whole grains — modest but reliable contributors

Cooking, freezing, and food processing destroy a meaningful fraction of B5 — refined grains lose roughly 50% of the vitamin compared to whole grains [3]. This is one reason whole, minimally processed foods score better on micronutrient density even when calorie content is similar.

Deficiency Is Rare — But Real When Induced

Naturally occurring isolated B5 deficiency is essentially never seen outside of severe general malnutrition. The classic experimental data comes from World War II prisoner-of-war camps in the Pacific theater, where a syndrome of painful, burning sensations in the feet ("burning feet syndrome") appeared in malnourished prisoners and improved with pantothenic acid supplementation [3]. Deliberate experimental deficiency studies in the 1950s using a B5 antagonist confirmed that humans develop fatigue, headache, sleep disturbance, mood changes, GI upset, and paresthesias when CoA biosynthesis is blocked [2][3].

The Acne Connection

For decades there were anecdotal reports that high-dose pantothenic acid could improve acne, with mechanistic hypotheses around fatty acid metabolism in sebaceous glands. The first quality randomized controlled trial appeared in 2014: Yang and colleagues randomized 48 adults with mild-to-moderate facial acne to a pantothenic acid–based supplement versus placebo for 12 weeks. The supplement group showed a statistically significant reduction in total facial lesion count versus placebo, with good tolerability [1]. This single trial is encouraging but not definitive — larger replications are still needed before B5 enters mainstream acne care, and dosing in the trial (a multi-ingredient supplement) was far above the AI.

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

The clinical importance of CoA biosynthesis becomes vivid in PKAN, a rare inherited neurodegenerative disease caused by mutations in PANK2, the gene encoding pantothenate kinase 2 — the first enzyme that converts pantothenic acid into CoA [5]. Children and adolescents with PKAN develop progressive movement disorders, dystonia, and characteristic iron accumulation in the basal ganglia visible on MRI ("eye of the tiger" sign). PKAN illustrates that even partial CoA-pathway impairment produces severe neurological consequences — a reminder that healthy CoA flux is non-negotiable for the brain.

Pantethine vs. Pantothenic Acid

Pantethine is a stable disulfide form of pantothenic acid that has been studied separately for cholesterol lowering at pharmacological doses (600–900 mg/day). Plain pantothenic acid at typical AI doses does not produce comparable lipid effects. See our Pantethine page for that evidence base.

Safety

There is no Tolerable Upper Intake Level (UL) for pantothenic acid because adverse effects from oral intake have not been documented at any dose tested [2][4]. Doses of 10 g/day have been used in clinical trials with only occasional GI upset (loose stools) reported. Pantothenic acid does not interfere with common laboratory assays the way high-dose biotin can.

Evidence Review

Biochemistry: A Settled Foundation

The role of pantothenic acid in CoA and ACP biosynthesis has been established since the 1940s and is not clinically controversial. Pantothenic acid combines with cysteine and ATP through a five-step pathway — pantothenate kinase, phosphopantothenoylcysteine synthetase, phosphopantothenoylcysteine decarboxylase, phosphopantetheine adenylyltransferase, and dephospho-CoA kinase — to produce CoA [3][5]. CoA derivatives participate in the synthesis and oxidation of fatty acids, the citric acid cycle (via acetyl-CoA), heme biosynthesis (via succinyl-CoA), cholesterol and steroid hormone synthesis (via HMG-CoA and acetyl-CoA), and the synthesis of neurotransmitters such as acetylcholine.

The Linus Pauling Institute review notes that approximately 4% of all known enzymes use CoA or an acyl-CoA derivative as substrate, and at any given moment human tissue contains roughly 100 nmol/g of CoA distributed across cytosolic, mitochondrial, and peroxisomal pools [3]. Mitochondria contain the highest concentrations because of their central role in fatty acid oxidation and the citric acid cycle.

Acne RCT (Yang 2014)

Yang and colleagues conducted the first published double-blind, placebo-controlled trial of pantothenic acid for acne vulgaris [1]. Forty-eight subjects aged 18–45 with mild-to-moderate facial acne were randomized 1:1 to a proprietary pantothenic acid–based dietary supplement or matched placebo for 12 weeks. The primary endpoint was change in total facial lesion count from baseline.

Key findings:

Total lesion count: significant reduction in the active group versus placebo at week 12 (p = 0.0223)
Inflammatory lesions: significantly reduced in the supplement group
Skin surface lesion count: improved with active treatment
Tolerability: no significant adverse events; supplement well-tolerated

Limitations are real: the active product was a multi-ingredient formulation containing pantothenic acid plus L-carnitine, thiamine, and other cofactors, so the trial cannot definitively isolate B5 as the active component. The sample was small and the trial single-center. The proposed mechanism — that adequate CoA supports beta-oxidation of fatty acids in sebaceous glands and reduces sebum lipid accumulation — remains hypothesis-level. Still, this is the best controlled human evidence to date that pantothenic acid–based supplementation can move acne endpoints versus placebo, and it justifies further trial work with isolated pantothenic acid at defined doses.

Dietary Requirements and Status Assessment

The Institute of Medicine set the Adequate Intake at 5 mg/day for adults based on observed mean intakes that maintain urinary excretion in a range associated with adequate CoA production [4]. EFSA conducted an independent review and arrived at the same 5 mg/day reference value, noting that no biomarker of pantothenic acid status has been validated for clinical use — there is no equivalent of homocysteine for folate or methylmalonic acid for B12 [6]. Whole-blood and erythrocyte pantothenic acid concentrations correlate weakly with intake; urinary excretion is the most commonly cited indicator but is sensitive to short-term intake and not robust for population status assessment.

NHANES dietary intake data summarized by NIH ODS indicate that average pantothenic acid intake in U.S. adults is approximately 5–6 mg/day, very close to the AI [2]. Inadequate intake is uncommon in healthy populations consuming a varied diet. Population subgroups with below-AI intake include some children and elderly individuals on highly restricted diets, but documented clinical deficiency is essentially absent in non-malnourished populations.

PKAN and the Therapeutic Frontier

Pantothenate kinase-associated neurodegeneration (PKAN) provides the clearest clinical demonstration of CoA pathway importance [5]. PKAN is autosomal recessive, caused by biallelic loss-of-function mutations in PANK2. Classical PKAN typically presents before age 6 with progressive dystonia, dysarthria, parkinsonism, and pigmentary retinopathy; atypical PKAN presents in the second decade with a more slowly progressive course. MRI shows characteristic iron accumulation and gliosis in the globus pallidus producing the "eye of the tiger" sign, present in essentially 100% of confirmed cases.

The key research insight is that bypassing the PANK2 defect — by supplementing downstream CoA precursors such as 4-phosphopantetheine — can partially restore CoA biosynthesis in patient-derived cells. Trials of fosmetpantotenate (a phosphopantothenate prodrug) ultimately failed to meet primary endpoints in advanced disease, but research continues into earlier intervention and alternative CoA-pathway substrates. PKAN does not respond meaningfully to ordinary pantothenic acid supplementation because the block is at the kinase step, downstream of the substrate.

Safety Profile

The absence of a UL reflects the absence of demonstrated toxicity, not absence of investigation [2][4]. Doses of 1–10 g/day have been used in human trials of pantethine and pantothenic acid for cholesterol, acne, and other indications. The most common adverse effect is mild diarrhea at multi-gram doses, attributable to osmotic effects rather than systemic toxicity. There are no documented drug interactions of clinical importance and no interference with laboratory assays at standard or supra-physiologic doses.

Evidence Strength Summary

Indication	Evidence Level	Notes
CoA / ACP cofactor function	Strong	Settled biochemistry; deficiency consequences clear
Maintaining adequacy at AI	Strong	NHANES intake near AI; clinical deficiency rare
Burning feet syndrome	Historical	WWII POW data; not relevant outside severe malnutrition
Acne (multi-ingredient formula)	Moderate	One positive RCT; needs replication with isolated B5
PKAN treatment	Insufficient	Pathway block downstream of substrate; investigational
Acne (isolated B5)	Insufficient	No quality RCT of plain pantothenic acid alone
Athletic performance	Weak	Small studies inconsistent; mechanism unclear

References

A Randomized, Double-Blind, Placebo-Controlled Study of a Novel Pantothenic Acid-Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne BlemishesYang M, Moclair B, Hatcher V, Avis T, Bucci L, Burrus M, Goldfaden R. Dermatology and Therapy, 2014. PubMed 24831048 →
Pantothenic Acid - Health Professional Fact SheetNIH Office of Dietary Supplements. National Institutes of Health, 2021. Source →
Pantothenic AcidLinus Pauling Institute Micronutrient Information Center. Oregon State University, 2015. Source →
Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and CholineInstitute of Medicine, Food and Nutrition Board. National Academies Press, 1998. Source →
Pantothenate Kinase-Associated NeurodegenerationHogarth P, Gregory A, Hayflick SJ. GeneReviews, NCBI Bookshelf, 2023. Source →
Dietary Reference Values for pantothenic acidEFSA Panel on Dietetic Products, Nutrition and Allergies. EFSA Journal, 2014. Source →